Basic Immunology of Vaccine Development

The Vaccine Book

Volumn , Issue , 2003, Pages 51-72

  Seder, Robert A ^a   Mascola, John R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3442889391     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50006-8     Document Type: Chapter

References (92)

1. Hoffmann J.A., et al. Phylogenetic perspectives in innate immunity. Science 1999, 284:1313-1318.
2. Medzhitov R., Janeway C.A. Innate immunity: The virtues of a nonclonal system of recognition. Cell 1997, 91:295-298.
3. Medzhitov R., Janeway C. Innate immunity. New. England J. Medicine 2000, 343:338-344.
4. Medzhitov R., Janeway C.A. Innate immunity: Impact on the adaptive immune response. Curr. Opin. Immunol. 1997, 9:4-9.
5. Lemaitre B., et al. The dorsoventral regulatory gene cassette spatzle/foll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
6. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
7. Poltorak A., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998, 282:2085-2088.
8. Brightbill H.D., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285:732-736.
9. Hemmi H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
10. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
11. Banchereau J., et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 1994, 12:881-922.
12. + T-helper and a T-killer cell. Nature 1998, 393:474-478.
13. Bennett S.R., et al. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
14. Schoenberger S.P., et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
15. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
16. + T cells. Annu. Rev. Immunol. 1994, 12:635-673.
17. Trinchieri G. Immunobiology of interleukin-12. Immunol. Res. 1998, 17:269-278.
18. Sprent J., Surh C.D. Generation and maintenance of memory T cells. Curr. Opin. Immunol. 2001, 13:248-254.
19. Zinkernagel R.M., et al. On immunological memory. Annu. Rev. Immunol. 1996, 14:333-367.
20. Ahmed R., Gray D. Immunological memory and protective immunity: Understanding their relation. Science 1996, 272:54-60.
21. + T-cell memory determined by clonal burst size. Nature 1994, 369:652-654.
22. McHeyzer-Williams M.G., Davis M.M. Antigen-specific development of primary and memory T cells in vivo. Science 1995, 268:106-111.
23. Oehen S., et al. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J. Exp. Med. 1992, 176:1273-1281.
24. Ochsenbein A.F., et al. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:9293-9298.
25. van Stipdonk M.J., Lemmens E.E., Schoenberger S.P. Naive CTL require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 2001, 2:423-429.
26. Wong P., Pamer E.G. Cutting edge: Antigen-independent CD8 T cell proliferation. J. Immunol. 2001, 166:5864-5868.
27. + T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2001, 2:415-422.
28. + T-cell memory. Nat. Med. 2001, 7:913-919.
29. Dutton R.W., Bradley L.M., Swain S.L. T cell memory. Annu. Rev. Immunol. 1998, 16:201-223.
30. + T cells to antigen stimulation in vivo. Nat. Immunol. 2000, 1:47-53.
31. Rogers P.R., Dubey C., Swain S.L. Qualitative changes accompany memory T cell generation: Faster, more effective responses at lower doses of antigen. J. Immunol. 2000, 164:2338-2346.
32. + T lymphocytes in vivo. J. Immunol. 1999, 162:766-773.
33. + T cells are hyperreactive to antigenic challenge in vitro. J. Exp. Med. 1996, 184:2141-2151.
34. Garcia S., DiSanto J., Stockinger B. Following the development of a CD4 T cell response in vivo: From activation to memory formation. Immunity 1999, 11:163-171.
35. Tanchot C., et al. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 1997, 276:2057-2062.
36. Sallusto F., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
37. Opferman J.T., Ober B.T., Ashton-Rickardt P.G. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999, 283:1745-1748.
38. Jacob J., Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature 1999, 399:593-597.
39. Gray D., Matzinger P. T cell memory is short-lived in the absence of antigen. J. Exp. Med. 1991, 174:969-974.
40. Kundig T.M., et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9716-9723.
41. Bachmann M.F., et al. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"?. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:640-645.
42. Lau L.L., et al. Cytotoxic T-cell memory without antigen. Nature 1994, 369:648-652.
43. Murali-Krishna K., et al. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999, 286:1377-1381.
44. Swain S.L. Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity 1994, 1:543-552.
45. Swain S.L., Hu H., Huston G. Class II-independent generation of CD4 memory T cells from effectors. Science 1999, 286:1381-1383.
46. Nishimura H., et al. Differential roles of interleukin-15 mRNA isoforms generated by alternative splicing in immune responses in vivo. J. Exp. Med. 2000, 191:157-170.
47. Kennedy M.K., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin-15-deficient mice. J. Exp. Med. 2000, 191:771-780.
48. + memory T cells by opposing cytokines. Science 2000, 288:675-678.
49. Lodolce J.P., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
50. Waldmann T.A., Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 1999, 17:19-49.
51. Schluns K.S., et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 2000, 1:426-432.
52. Stobie L., et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8427-8432.
53. Gurunathan S., et al. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 1998, 4:1409-1415.
54. Heinzel F.P. Antibodies. Principles and Practice of Infectious Diseases 2000, 45-66. Churchill Livingstone, Philadelphia. G. Mandell, J. Bennett, R. Dolin (Eds.).
55. Frazer J.K., Capra J.D. Immunoglobulins: Structure and function. Fundamental Immunology 1999, 37-74. Lippincott-Raven, Philadelphia. W.E. Paul (Ed.).
56. Ada G. The immunology of vaccination. Vaccines 1999, 28-39. W. B. Saunders Company, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
57. Krause R.M., Dimmock N.J., Morens D.M. Summary of antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J. Infect. Dis. 1997, 176:549-559. 3.
58. Robbins J.B., Schneerson R., Szu S.C. Perspective: hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 1995, 171:1387-1398.
59. Tonegawa S. Somatic generation of antibody diversity. Nature 1983, 302:575-581.
60. Delves P.J., Roitt I.M. The immune system. First of two parts. New England J. Medicine 2000, 343:37-49.
61. Schwartz R.S. Jumping genes and the immunoglobulin V gene system. New. England J. Medicine 1995, 333:42-44.
62. Nossal G.J. Host immunobiology and vaccine development. Lancet 1997, 350:1316-1319.
63. Huston D.P. The biology of the immune system. J. Am. Med. Assoc. 1997, 278:1804-1814.
64. Garside P., et al. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998, 281:96-99.
65. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
66. Spellberg B., Edwards J.E. Type 1/Type 2 immunity in infectious diseases. Clin. Infect. Dis. 2001, 32:76-102.
67. Ward J.I., Zangwill K.M. Haemophilus influenzae vaccines. Vaccines 1999, 183-221. W. B. Saunders Company, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
68. Fedson D.S., Musher D.M., Eskola J. Pneumococcal vaccine. Vaccines 1999, 553-607. W. B. Saunders Company, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
69. Geha R.S., Rosen F.S. The genetic basis of immunoglobulin-class switching. New England J. Medicine 1994, 330:1008-1009.
70. Liu Y.J. Sites of B lymphocyte selection, activation, and tolerance in spleen. J. Exp. Med. 1997, 186:625-629.
71. Foote J., Milstein C. Kinetic maturation of an immune response. Nature 1991, 352:530-532.
72. Jacob J., et al. Intraclonal generation of antibody mutants in germinal centres. Nature 1991, 354:389-392.
73. Slifka M.K., et al. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8:363-372.
74. Manz R.A., Thiel A., Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997, 388:133-134.
75. Dittmer U., Brooks D.M., Hasenkrug K.J. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat. Med. 1999, 5:189-193.
76. Zinkernagel R.M. Immunology taught by viruses. Science 1996, 271:173-178.
77. Parren P.W., Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 2001, 77:195-262.
78. Lutwick L.I. Postexposure prophyslaxis. Infect. Dis. Clin. North Am. 1996, 10:899-915.
79. Mazanec M.B., et al. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:6901-6905.
80. Bomsel M., et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9:277-287.
81. Burns J.W., et al. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272:104-107.
82. Afonso L.C., et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263:235-237.
83. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18:927-974.
84. Wagner H. Toll meets bacterial CpG-DNA. Immunity 2001, 14:499-502.
85. + T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 1999, 170:29-38.
86. Seder R.A., Gurunathan S. DNA vaccines-Designer vaccines for the 21st century. New England J. Medicine 1999, 341:277-278.
87. Wang R., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
88. Le T.P., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000, 18:1893-1901.
89. Calarota S., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351:1320-1325.
90. Barouch D.H., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
91. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4:397-402.
92. Amara R.R., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.